Wedbush Reiterates “Outperform” Rating for Cidara Therapeutics Inc (CDTX)

Cidara Therapeutics Inc (NASDAQ:CDTX)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research note issued on Tuesday. They presently have a $13.00 price objective on the biotechnology company’s stock. Wedbush’s target price suggests a potential upside of 75.68% from the stock’s current price.

A number of other brokerages have also weighed in on CDTX. Needham & Company LLC lowered their target price on Cidara Therapeutics from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, February 21st. BTIG Research reaffirmed a “buy” rating and set a $20.00 target price (up from $15.00) on shares of Cidara Therapeutics in a research report on Saturday, April 29th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 target price on shares of Cidara Therapeutics in a research report on Thursday, March 16th. Jefferies Group LLC reissued a “buy” rating and issued a $15.00 price target on shares of Cidara Therapeutics in a research report on Friday, March 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 price target (down from $25.00) on shares of Cidara Therapeutics in a research report on Wednesday, February 22nd. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $12.77.

Analyst Recommendations for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ:CDTX) opened at 7.40 on Tuesday. The company’s market capitalization is $124.36 million. The stock’s 50 day moving average is $7.20 and its 200 day moving average is $8.99. Cidara Therapeutics has a 52 week low of $6.10 and a 52 week high of $12.95.

Cidara Therapeutics (NASDAQ:CDTX) last issued its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.10. Analysts predict that Cidara Therapeutics will post ($3.41) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was reported by sleekmoney and is the property of of sleekmoney. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://sleekmoney.com/wedbush-reiterates-outperform-rating-for-cidara-therapeutics-inc-cdtx-2/1824892.html.

In related news, CEO Jeffrey Stein purchased 12,900 shares of the stock in a transaction that occurred on Friday, March 31st. The stock was acquired at an average cost of $7.75 per share, with a total value of $99,975.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kevin Forrest purchased 12,500 shares of the stock in a transaction that occurred on Friday, March 31st. The stock was bought at an average cost of $7.75 per share, with a total value of $96,875.00. The disclosure for this purchase can be found here. Corporate insiders own 22.20% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. West Family Investments Inc. bought a new stake in Cidara Therapeutics during the first quarter worth approximately $780,000. Teachers Advisors LLC increased its position in shares of Cidara Therapeutics by 17.5% in the fourth quarter. Teachers Advisors LLC now owns 16,524 shares of the biotechnology company’s stock worth $172,000 after buying an additional 2,458 shares during the period. Perceptive Advisors LLC acquired a new position in shares of Cidara Therapeutics during the fourth quarter worth about $8,043,000. Alyeska Investment Group L.P. acquired a new position in shares of Cidara Therapeutics during the fourth quarter worth about $1,040,000. Finally, Broadfin Capital LLC increased its position in shares of Cidara Therapeutics by 237.3% in the fourth quarter. Broadfin Capital LLC now owns 562,875 shares of the biotechnology company’s stock worth $5,854,000 after buying an additional 396,000 shares during the period. 47.34% of the stock is owned by institutional investors and hedge funds.

About Cidara Therapeutics

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

5 Day Chart for NASDAQ:CDTX

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/wedbush-reiterates-outperform-rating-for-cidara-therapeutics-inc-cdtx-2/1824892.html

Receive News & Ratings for Cidara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *